Press Detail





News: Biotest AG: Voluntary recall of human albumin

News: Biotest AG / Key word(s): Profit Warning
Biotest AG: Voluntary recall of human albumin

26.04.2017 / 17:48
The issuer is solely responsible for the content of this announcement.



/

PRESS RELEASE


Biotest: Voluntary recall of human albumin

- Already quarantined batches of human albumin are recalled

- Consequences of the one-time effect on Sales and EBIT are currently being
evaluated

- As a precaution, guidance is being reduced

Dreieich, 26 April 2017 Today, Biotest has informed its customers about the
recall of several batches of human albumin. The batches in question had
already been quarantined by Biotest as a precautionary measure on 13 April
2017. Since that day, no affected product had been used. By recalling the
affected products, Biotest ensures that all products are being returned.

An equipment failure in the production of an albumin intermediate gave
reason for this action. The equipment failure has already been fixed.

The recall is performed in close co-operation with the regulatory
authorities. Further information is available on our website:
http://www.biotest.com/de/en/products.cfm

After repairing of the equipment failure, the original production range has
already been reached again. This one-time effect will only impact the fiscal
year 2017. Consequences on Sales and EBIT are currently being evaluated. As
a precaution, Biotest reduces its Sales guidance from low single-digit
growth rate to the level of the previous year and its EBIT guidance of EUR46
to EUR48 million by EUR25 to EUR30 million.

About Human Albumin
Albumin is used in particular in intensive care medicine and acute care.
Patients with extensive blood or fluid loss, due to burns among other
things, have too little of the important proteins in their blood. This
protein loss is compensated by administering Albumin. Albumin is also used
for volume replacement in cases of blood poisoning. Unlike synthetically
manufactured drugs, Albumin produced from human plasma offers particularly
good tolerability. It is also the most important protein carrier in the
blood for binding and removing (harmful) substances from the vascular
system.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and markets
immunoglobulins, coagulation factors and albumins based on human blood
plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus which
are produced by recombinant technologies. Biotest has more than 2,500
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich,
Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.




26.04.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de



Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange



End of News DGAP News Service


567855 26.04.2017